Article Correctness Is Author's Responsibility: Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemia

(Fred Hutchinson Cancer Research Center) Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse. The findings provide the basis for launching a first-in-human clinical trial of this new immunotherapy, which relies on engineered T-cell receptors, or TCRs.